X
Access Company Profiles

Get business overview, business operations details specific to this market, products and services, latest developments and more...

Business Email

Select Companies

 

Japan Pharmaceutical Companies (2024 - 2029)

Several global pharmaceutical companies are making significant strides in the medical field. These firms are renowned for their contributions to healthcare, with their efforts spanning from developing new drugs to improving existing treatments. These corporations have a strong presence in the industry, with their innovative approaches and commitment to research and development. Their contributions have greatly impacted healthcare, providing solutions to various health challenges and improving the quality of life for patients worldwide.

Home Market Analysis Healthcare Research Pharmaceuticals Research Japan Pharmaceutical Industry Companies

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Top Companies in Japan Pharmaceutical Market

This report lists the top Japan Pharmaceutical companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Japan Pharmaceutical industry.

  1. Takeda Pharmaceuticals

  2. Pfizer

  3. Chugai Pharmaceutical

  4. Merck

  5. Daiichi Sankyo

*Disclaimer: Top companies sorted in no particular order

Japan Pharmaceutical Market Major Players

Japan Pharmaceutical Market Concentration

Japan Pharmaceutical Market Concentration

Japan Pharmaceutical Company List

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

      1. 4.1.1 Healthcare Expenditure

      2. 4.1.2 Pharmaceutical Imports and Exports

      3. 4.1.3 Epidemiology Data For key Diseases

      4. 4.1.4 Regulatory Landscape/Regulatory Bodies

      5. 4.1.5 Licensing and Market Authorization

      6. 4.1.6 Pipeline Analysis

        1. 4.1.6.1 By Phase

        2. 4.1.6.2 By Sponsor

        3. 4.1.6.3 By Disease

      7. 4.1.7 Statically Overview

        1. 4.1.7.1 Number of Hospitals

        2. 4.1.7.2 Employment in the Pharmaceutical Sector

        3. 4.1.7.3 R&D Expenditure

      8. 4.1.8 Ease of Doing Business

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Geriatric Population and Increasing Burden of Chronic Diseases

      2. 4.2.2 Increasing Research and Development Activities Along with Growing R&D Investments

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulatory Scenario

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 By Therapeutic Category

      1. 5.1.1 Antiallergics

      2. 5.1.2 Blood and Blood Forming Organs

      3. 5.1.3 Cardiovascular System

      4. 5.1.4 Dermatologicals

      5. 5.1.5 Genito Urinary System

      6. 5.1.6 Respiratory System

      7. 5.1.7 Sensory Organs

      8. 5.1.8 Other Therapeutic Categories

    2. 5.2 By Prescription Type

      1. 5.2.1 Prescription Drugs

        1. 5.2.1.1 Branded

        2. 5.2.1.2 Generics

      2. 5.2.2 OTC Drugs

  6. 6. COMPETITIVE LANDSCAPE AND COMPANY PROFILES

    1. 6.1 Company Profiles

      1. 6.1.1 Takeda Pharmaceutical Company Limited

      2. 6.1.2 Astellas Pharma Inc.

      3. 6.1.3 Pfizer Inc.

      4. 6.1.4 Chugai Pharmaceutical Co. Ltd

      5. 6.1.5 Merck & Co. Inc.

      6. 6.1.6 Daiichi Sankyo Company Limited

      7. 6.1.7 Bayer AG

      8. 6.1.8 GlaxoSmithKline PLC

      9. 6.1.9 Eli Lilly and Company

      10. 6.1.10 Novartis International AG

      11. 6.1.11 Sanofi SA

      12. 6.1.12 Catalent Inc.

      13. 6.1.13 Eisai Co. Ltd

      14. 6.1.14 Johnson and Johnson (Janssen Global Services)

      15. 6.1.15 Aspen Holdings

    2. *List Not Exhaustive

  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS


Specific to Japan Pharmaceutical Market
Need More Details On Market Players And Competitors?
Download PDF

Competitive Landscape Report Includes

Company Profiles (includes Global Level Overview, Market Level Overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and Analysis of Recent Developments). Key Strategic Moves, Market Share Analysis, Company Landscape, and List of Companies.

Japan Pharmaceutical Market Companies Summary

The pharmaceutical market in Japan has been significantly impacted by the COVID-19 pandemic, with an increased demand for prescription drugs and vaccines. This has led to a surge in the import of pharmaceutical products, particularly COVID-19 vaccines. The Japanese government's emergency approval of COVID-19 vaccines and drugs has further stimulated the market's growth. As pandemic-related restrictions relax and companies resume their activities in manufacturing drugs and other products, the pharmaceutical market is expected to continue growing. The market's growth is also being driven by factors such as the rising geriatric population, increasing incidence of chronic diseases, and growing research and development investments. The rising number of infections and chronic diseases is driving the demand for pharmaceutical products. The expected increase in the number of people suffering from cancer and dementia is anticipated to increase the demand for effective drugs. The increasing geriatric population, which is more prone to develop chronic diseases, is raising the demand for effective therapeutics. The increasing focus on research and development activities and rising research and health expenditure is expected to increase the development and availability of pharmaceutical products. The pharmaceutical market in Japan is highly competitive and consists of several major players, with a few dominating the market. Some key players are making acquisitions and joint ventures with other companies to consolidate their market positions.

Explore More

Japan Pharmaceutical Companies - Table of Contents

  1. 1. COMPETITIVE LANDSCAPE AND COMPANY PROFILES

    1. 1.1 Company Profiles

      1. 1.1.1 Takeda Pharmaceutical Company Limited

      2. 1.1.2 Astellas Pharma Inc.

      3. 1.1.3 Pfizer Inc.

      4. 1.1.4 Chugai Pharmaceutical Co. Ltd

      5. 1.1.5 Merck & Co. Inc.

      6. 1.1.6 Daiichi Sankyo Company Limited

      7. 1.1.7 Bayer AG

      8. 1.1.8 GlaxoSmithKline PLC

      9. 1.1.9 Eli Lilly and Company

      10. 1.1.10 Novartis International AG

      11. 1.1.11 Sanofi SA

      12. 1.1.12 Catalent Inc.

      13. 1.1.13 Eisai Co. Ltd

      14. 1.1.14 Johnson and Johnson (Janssen Global Services)

      15. 1.1.15 Aspen Holdings

    2. *List Not Exhaustive

Japan Pharmaceutical Companies FAQs

Takeda Pharmaceutical Company Limited, Pfizer Inc., Chugai Pharmaceutical Co., Ltd., Merck & Co., Inc. and Daiichi Sankyo Company, Limited are the major companies operating in the Japan Pharmaceutical Market.

Japan Pharma Market Report Snapshots

Japan Pharmaceutical Market Size - Industry Report on Share, Growth Trends & Forecasts Analysis (2024 - 2029)